Reviva Pharmaceuticals Holdings, Inc (RVPH)

By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT First Quarter 2022 Financial and Operational Results On May 16, 2022, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) announced first quarter 2022 financial and operational results and filed its Form 10-Q with the SEC. On February 1, 2022, Reviva announced that the first patients had been dosed in the Phase III RECOVER

CUPERTINO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright Global Investment Conference being held May

Reviva Pharmaceuticals (NASDAQ:RVPH) reported its Q1 earnings results on Monday, May 16, 2022 at 04:05 PM. Here's what investors need ...

- Hosted key opinion leader (KOL) webinar on brilaroxazine for schizophrenia and other neuropsychiatric disorders led by industry thought leaders Leslie Citrome, MD & Larry Ereshefsky, PharmD - Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023 - - $23.4 Million in Cash as of March 31, 2022 - CUPERTINO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”),

On Wednesday, 807 companies reached new 52-week lows. Things to Consider About Today's 52-Week Lows: Amazon.com ...

CUPERTINO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that the RECOVER study is progressing well and all sites in the United States (U.S.) have been initiated. Global sites in Europe and India remain on

Virtual event on Tuesday, May 3rd at 10:00 AM ET An overview of unmet medical needs and therapeutic opportunities in schizophrenia and major neuropsychiatric disorders will be discussed CUPERTINO, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic dis

Gainers IMAC Holdings (NASDAQ:IMAC) shares increased by 60.0% to $1.6 during Thursday's pre-market session. The market value of their ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're diving into the biggest pre-market stock movers for Thursday that investors are going to want to keep track of today. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. 10 Stocks Are Issuing Sell Signals Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

CUPERTINO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today announced that an interview with Founder, President and CEO Dr. Laxminarayan Bhat will air on The RedChip Money Report® on Bloomberg TV, March 26, at 7 p.m. Eastern Time (ET

CUPERTINO, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat and one-on-one investor meetings at the M

- 5th Annual Neuroscience Innovation Forum - - BIO-Europe Spring® 2022 - CUPERTINO, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will

By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT Fourth Quarter and Fiscal Year 2021 Financial and Operational Results On March 15, 2022, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) announced fourth quarter and fiscal year 2021 financial and operational results and filed its Form 10-K with the SEC. On February 1, 2022, Reviva announced that the first patients had

- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023 - $29.7 Million in Cash as of December 31, 2021 - CUPERTINO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammato

Gainers Second Sight Medical (NASDAQ:EYES) stock increased by 7.8% to $1.51 during Tuesday's pre-market session. The ...

- RECOVER is a Phase 3, randomized, double-blind study with registrational intent - - Reviva anticipates expanding the clinical development of brilaroxazine into other neuropsychiatric indications - CUPERTINO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory di

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, trader! It's time to get this week going with a breakdown of the biggest pre-market stock movers for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

Gainers Acorda Therapeutics (NASDAQ:ACOR) stock rose 6.7% to $1.92 during Wednesday's after-market session. The company's market cap ...

Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever ...

Gainers Rockwell Medical (NASDAQ:RMTI) stock rose 27.5% to $0.51 during Thursday's regular session. As of 12:32 EST, this security is ...

Gainers Immuron (NASDAQ:IMRN) shares rose 36.6% to $3.58 during Wednesday's regular session. Trading volume for this ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Grab a cup of coffee and get ready for another busy day of trading as we start with the biggest pre-market stock movers for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT FDA ‘Study May Proceed’ Letter Received Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) announced on January 10, 2022 the receipt of a May Proceed letter from the FDA regarding pivotal Phase III clinical trials for brilaroxazine in schizophrenia, including one long-term safety trial. Through the letter, the FDA allowed

Gainers Inari Medical (NASDAQ:NARI) stock moved upwards by 9.7% to $93.0 during Monday's after-market session. This security traded ...

The FDA has notifiedReviva Pharmaceuticals Holdings Inc(NASDAQ: RVPH)that it may proceed with Phase 3 trialof ...

- Brilaroxazine is a novel serotonin and dopamine receptor modulator currently being developed for diseases with dysfunctional serotonin signaling including neuropsychiatric and pulmonary indications - - Initiation of both Phase 3 trials is expected by end of January 2022 - CUPERTINO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of

CUPERTINO, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following conferences in January and invites investors

By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT Third Quarter 2021 Financial and Operational Results On November 15, 2021, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) announced third quarter 2021 financial and operational results and filed its Form 10-Q with the SEC for the period ending September 30, 2021. Reviva is on the cusp of launching its Phase III

- Initiation of a pivotal Phase 3 trial evaluating the efficacy and safety of brilaroxazine for the treatment of schizophrenia expected by year-end - - Additional Phase 3 trial evaluating the long-term safety of brilaroxazine in adult patients with schizophrenia expected to begin by year-end - - $33.5 Million in Cash as of September 30, 2021 - CUPERTINO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage ph

CUPERTINO, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Benzinga Healthcare Small Cap Conference as well as parti